: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook
: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC) trxc stock buy or sell
: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout. : Leading up to its acquisition, the company
: On August 22, 2024, KARL STORZ finalized its acquisition of Asensus Surgical. : On August 22, 2024, KARL STORZ finalized
: Under the terms of the merger agreement, all outstanding shares of ASXC were acquired for $0.35 per share in cash .
: In March 2021, the company changed its name from TransEnterix to Asensus Surgical to align with its focus on "Performance-Guided Surgery".
The ticker is no longer active for trading. TransEnterix, the company originally associated with that symbol, rebranded as Asensus Surgical and changed its ticker to ASXC in March 2021. Subsequently, Asensus Surgical was acquired by KARL STORZ and its stock was officially delisted in August 2024. Stock Status and Delisting